New Drug Combination Shows Promising Activity in Non-Small Cell Lung Cancer Patients.

[2greys]

Patients with non-small cell lung cancer (NSCLC) now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors (ICI). Despite these changes, many patients still develop progressive disease after ICI treatment. In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers describe promising results from an early clinical trial that may offer patients who progress after ICI an additional treatment option.

moffitt.org/newsroom/press-...

[HungryHufflepuff]

Are those in the same category as Benralizumab and Omalizumab (or maybe they were mentioned in that article and I missed them) and what is that category of medicine? Things ending in -zumab seem to be cropping up a lot lately and I don't recall seeing those names previously.

🥑